PULSE, a non-inferiority study of maintenance Pembro at Usual or Low doSE

Dr Jordi Remon Masip, medical oncologist at Institut Gustave Roussy, Villejuif, France presents PULSE, a non-inferiority study of maintenance pembrolizumab at usual or low dose (based on increased interval time between 2 infusions) in non-squamous lung cancer. The trial also runs in Belgium and is still open for inclusion.